Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification.

Resectable Clinical N2 Non–Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer Ramón Rami-Porta, MD, FETCS,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

John E. Pilling, FRCS (CTh), Michael E

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure Jessamy A. Boyd, MD, Jessica L. Hubbs,

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

The International Association for the Study of Lung Cancer Lung Cancer Staging Project Hisao Asamura, MD, Kari Chansky, MS, John Crowley, PhD, Peter.

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database Valerie W. Rusch, MD, Dorothy Giroux, Catherine.

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases Marc Riquet, MD, PhD, Patrick Bagan,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung Cancer Following Resection Jenny K. Hoang, MBBS, FRANZCR, Edward Patz, MD, Dorothy Giroux, MS, Peter Goldstraw, FRCS Journal of Thoracic Oncology Volume 2, Issue 12, Pages 1103-1106 (December 2007) DOI: 10.1097/JTO.0b013e31815c04b4 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Survival for patients with pathological stage I non-small cell lung cancer. Clinical N0 versus clinical N1–N2. Median survival times were 102 and 107 months for patients with clinical stage I and II–IIIA (excluding T3N0M0), respectively (hazard ratio 1.16, p = 0.01), shown in the Kaplan-Meier survival curve. The survival curves converge at 8 years postsurgery. The 95% confidence limits for the median survival time (MST) estimates are shown in parentheses. Journal of Thoracic Oncology 2007 2, 1103-1106DOI: (10.1097/JTO.0b013e31815c04b4) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Non-contrast computed tomography scan of the thorax shows a cavitary right upper lobe non-small cell lung cancer and enlarged right paratracheal (Station 4R) lymph node (arrow). Mediastinoscopy was performed, and there was no evidence of lymph node metastasis on pathological evaluation. All nodes were reactive. Journal of Thoracic Oncology 2007 2, 1103-1106DOI: (10.1097/JTO.0b013e31815c04b4) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Survival for pathological stage I according to histology. Survival curves with 95% confidence limits for the median survival time (MST) estimates are shown in parentheses. Journal of Thoracic Oncology 2007 2, 1103-1106DOI: (10.1097/JTO.0b013e31815c04b4) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions